Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081614 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00081614 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 100 participants.
The verdict
NCT00081614, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will be to determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic renal cell carcinoma (RCC) with regard to time to progression, response rate, duration of response, and survival compared with Avastin alone. Since Avastin has been shown to be active in renal cancer, the goal will be to assess whether this activity can be enhanced with Erlotinib.
Interventions
- DRUG Avastin (bevacizumab)
- DRUG Tarceva (erlotinib HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081614
The ClinicalTrials.gov registry entry for NCT00081614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avastin (bevacizumab) is the first listed.
NCT00081614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081614 about?
NCT00081614 is a clinical study titled "A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma". The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will be to determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic renal cell carcinoma (R...
What is the current status of trial NCT00081614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2004-03. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00081614?
The interventions under investigation include: Avastin (bevacizumab) (DRUG), Tarceva (erlotinib HCl) (DRUG).
Who is sponsoring clinical trial NCT00081614?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.